Perceptive Advisors LLC Morphic Holding, Inc. Transaction History

Perceptive Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $6.16 Million - $9.32 Million	231,241 Added 405.83%	288,221 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $1.14 Million - $1.77 Million	56,980 New	56,980 $1.65 Million
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $2.77 Million - $5.18 Million	-106,460 Reduced 29.31%	256,737 $9.66 Million
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $7.98 Million - $17.4 Million	-404,130 Reduced 52.67%	363,197 $7.88 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $2.51 Million - $3.6 Million	-69,194 Reduced 8.27%	767,327 $30.8 Million
Q4 2021 Feb 14, 2022	SELL	$43.27 - $65.72 $2.2 Million - $3.34 Million	-50,819 Reduced 5.73%	836,521 $39.6 Million
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $2.72 Million - $3.43 Million	-50,800 Reduced 5.41%	887,340 $50.3 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $13.4 Million - $38.3 Million	451,140 Added 92.64%	938,140 $59.4 Million
Q3 2020 Nov 16, 2020	SELL	$22.51 - $30.11 $3.67 Million - $4.91 Million	-163,000 Reduced 25.08%	487,000 $13.3 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $19.82 $11.7 Million - $12.9 Million	650,000 New	650,000 $12.9 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.